Antibodies from Sinovac's Covid-19 shot fade after about 6 months, booster helps: study

Published July 26, 2021
The study was conducted by researchers at disease control authorities in Jiangsu province, Sinovac, and other Chinese institutions. — AFP/File
The study was conducted by researchers at disease control authorities in Jiangsu province, Sinovac, and other Chinese institutions. — AFP/File

Antibodies triggered by Sinovac Biotech's Covid-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.

Chinese researchers reported the findings from a study of blood samples from healthy adults aged between 18-59 in a paper published on Sunday, which has not been peer reviewed.

For participants receiving two doses, two or four weeks apart, only 16.9 per cent and 35.2pc, respectively, still had a level of neutralising antibodies above the threshold six months after the second dose, the paper said.

Those readings were based on data from two cohorts involving more than 50 participants each, while the study gave third doses to a total of 540 participants.

When participants in some cohorts were given a third dose, about six months after the second, neutralising antibody levels after a further 28 days had increased around 3-5 fold from the levels seen four weeks after the second dose, the study showed.

The study was conducted by researchers at disease control authorities in Jiangsu province, Sinovac, and other Chinese institutions.

Researchers cautioned the study did not test the antibodies' effect against more transmissible variants, and that further research was needed to assess antibody duration after a third shot.

Last month, Sinovac spokesman Liu Peicheng told Reuters preliminary results from blood samples of the vaccinated showed a three-fold reduction in neutralising effect against the Delta variant and suggested a third Sinovac shot could elicit more durable antibody reaction.

Earlier this month, Thailand announced it would use AstraZeneca's Covid-19 vaccine as a second dose for those who received Sinovac's shot as their first dose in a bid to increase protection.

The move was the first publicly announced mix-and-match of a Chinese vaccine and a Western-developed shot, as a new preliminary Thai study raised doubts about the longer-term protection of the two-dose Sinovac vaccine.

The announcement came after Thailand's health ministry said 618 medical workers out of 677,348 personnel who received two doses of the Sinovac vaccine became infected from April to July. One nurse died.

Neighbouring Indonesia has also reported breakthrough infections among medical and frontline workers who are fully inoculated with the Sinovac vaccine.

Opinion

Editorial

02 Dec 2021

Funding for polls

THE PTI government’s autocratic mentality is again on full display, even as it feigns adherence to the law....
02 Dec 2021

Soaring prices

PRICES are surging. And they are increasing at a much faster pace than anticipated, burdening millions of...
Ali Wazir’s bail
Updated 02 Dec 2021

Ali Wazir’s bail

IT has been a long time coming, but MNA and Pashtun Tahaffuz Movement leader Ali Wazir has finally been granted bail...
Covid funds controversy
Updated 01 Dec 2021

Covid funds controversy

A COMPREHENSIVE and detailed report by the auditor general of Pakistan on the utilisation of Covid-19 funds by the...
01 Dec 2021

Sindh LG law

THE Sindh Local Government Act, 2013, introduced by the PPP to roll back the Musharraf-era local bodies system in ...
Monster of circular debt
Updated 01 Dec 2021

Monster of circular debt

The crisis facing the energy sector cannot be tackled sustainably without taming the many elephants in the room.